Segal H, Cottam S, Potter D, Hunt B J
Department of Research Haematology, Harefield Hospital, London, England.
Hepatology. 1997 Mar;25(3):683-8. doi: 10.1002/hep.510250332.
Cirrhosis is associated with compromised hemostasis and coagulopathy during orthotopic liver transplantation (OLT). It has been suggested that hemostasis is better preserved during OLT in primary biliary cirrhosis (PBC) than other cirrhotic states. The aim of this study was to compare coagulation and fibrinolysis in 15 patients with PBC with 31 patients with other liver disease before and during OLT. Preoperatively, both groups had subnormal mean levels of prekallikrein, factor XIIa, antithrombin III (ATIII), plasminogen, and alpha2-antiplasmin. C1 esterase inhibitor and kallikrein inhibition in PBC was higher than the normal range (P < .01), but not in non-PBC. Non-PBC had lower median fibrinogen levels and shorter euglobulin clot lysis times (ECLT) (P < .05). Tissue plasminogen activator (tPA) antigen levels did not differ between groups but were elevated from the normal range, as were median thrombin-antithrombin complexes (TAT). Plasminogen activator inhibitor (PAI) activity was significantly higher in PBC (0.0041). Perioperatively in the PBC group during the early anhepatic phase of OLT, there was more thrombin generation, as evidenced by higher TAT levels (P = .0455) and less hyperfibrinolysis with longer ECLTs. We hypothesize that there is a preserved capacity to generate thrombin and less fibrinolytic activation during the anhepatic phase of OLT, and we suggest that, in PBC, the use of antifibrinolytic agents may have an adverse effect.
在原位肝移植(OLT)过程中,肝硬化与止血功能受损和凝血病相关。有人提出,与其他肝硬化状态相比,原发性胆汁性肝硬化(PBC)患者在OLT期间止血功能保留得更好。本研究的目的是比较15例PBC患者和31例其他肝病患者在OLT术前和术中的凝血及纤溶情况。术前,两组的前激肽释放酶、因子XIIa、抗凝血酶III(ATIII)、纤溶酶原和α2-抗纤溶酶的平均水平均低于正常。PBC患者的C1酯酶抑制剂和激肽释放酶抑制高于正常范围(P <.01),而非PBC患者则不然。非PBC患者的纤维蛋白原水平中位数较低,优球蛋白凝块溶解时间(ECLT)较短(P <.05)。两组间组织纤溶酶原激活物(tPA)抗原水平无差异,但均高于正常范围,凝血酶-抗凝血酶复合物(TAT)中位数也是如此。PBC患者的纤溶酶原激活物抑制剂(PAI)活性显著更高(0.0041)。在PBC组OLT的早期无肝期围手术期,有更多的凝血酶生成,TAT水平更高(P = 0.0455)证明了这一点,且由于ECLT延长,纤溶亢进程度较低。我们推测,在OLT的无肝期有保留的凝血酶生成能力和较少的纤溶激活,并且我们认为,在PBC中,使用抗纤溶药物可能有不良影响。